On May 1, 2018 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported that it will host a conference call on Tuesday, May 8, 2018, at 4:30 p.m. ET to review its first quarter 2018 financial results and provide an update on the company (Press release, Infinity Pharmaceuticals, MAY 1, 2018, View Source [SID1234525913]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the conference call can be accessed in the Investors/Media section of Infinity’s website at www.infi.com. To participate in the conference call, please dial 1-877-316-5293 (domestic) and 1-631-291-4526 (international) five minutes prior to start time. The conference ID number is 2479309. An archived version of the webcast will be available on Infinity’s website for 30 days.

On May 1, 2018 Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, reported that the company’s management team will present at Deutsche Bank’s 43rd Annual Health Care Conference being held at the Intercontinental Hotel Boston on Tuesday, May 8th at 1:35 p.m. EDT (Press release, Endocyte, MAY 1, 2018, View Source [SID1234525912]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the Company’s presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte’s website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company’s website for 90 days following the conference.

On May 1, 2018 Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) reported that the Company will release its 2018 first quarter financial results on Thursday, May 10, 2018, before the market opens (Press release, Eagle Pharmaceuticals, MAY 1, 2018, View Source [SID1234525911]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date Thursday, May 10, 2018
Time 8:30 a.m. EDT
Toll free (U.S.) 877-876-9176
International 785-424-1667
Webcast (live and replay)
www.eagleus.com, under the "Investor Relations" section

A replay of the conference call will be available for one week after the call’s completion by dialing 800-839-3735 (US) or 402-220-2977 (International) and entering conference call ID EGRXQ118. The webcast will be archived for 30 days at the aforementioned URL.

On May 1, 2018 Diplomat Pharmacy, Inc. (NYSE: DPLO), reported that executives will attend the 43rd Annual Deutsche Bank Health Care Conference in Boston (Press release, Diplomat Speciality Pharmacy, MAY 1, 2018, View Source [SID1234525910]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interim CEO Jeff Park, President Joel Saban, and Chief Financial Officer Atul Kavthekar are scheduled to present at 12:50 p.m. ET Wednesday, May 9.

A live audio-only webcast of the presentation and related materials will be available on the investor relations section of Diplomat’s website at ir.diplomat.is. The webcast and presentation materials will be online for 90 days.

On May 1, 2018 CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, reported its first quarter 2018 financial results on Wednesday, May 9, 2018, after the NASDAQ market close (Press release, CytomX Therapeutics, MAY 1, 2018, View Source;p=RssLanding&cat=news&id=2346043 [SID1234525909]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will not be conducting a conference call in connection with this financial results press release.